Form 8-K - Current report:
SEC Accession No. 0001654954-25-009510
Filing Date
2025-08-13
Accepted
2025-08-13 16:21:06
Documents
16
Period of Report
2025-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tennx_8k.htm   iXBRL 8-K 24075
2 PRESS RELEASE tennx_ex991.htm EX-99.1 65985
8 tennx_ex991img3.jpg GRAPHIC 3424
  Complete submission text file 0001654954-25-009510.txt   218645

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tennx-20250813.xsd EX-101.SCH 5030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tennx-20250813_lab.xml EX-101.LAB 14667
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tennx-20250813_cal.xml EX-101.CAL 901
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tennx-20250813_pre.xml EX-101.PRE 9278
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tennx-20250813_def.xml EX-101.DEF 2102
18 EXTRACTED XBRL INSTANCE DOCUMENT tennx_8k_htm.xml XML 3911
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 251211980
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)